SciSparc Ltd.(SPRC)Earnings, Financials & Key Ratios
SPRC•NASDAQ
$5.70
Price updated Jun 27, 2026
AboutSciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.Show more
- Revenue$856K-34.5%
- EBITDA-$9M-24.6%
- Net Income-$12M-93.8%
- EPS (Diluted)-882.64-8980.7%
- Gross Margin73.72%+90.3%
- EBITDA Margin-994.74%-90.1%
- Operating Margin-1022.08%-82.5%
- Net Margin-1422.78%-195.7%
- ROE-172.92%-154.9%
SPRC Price & Volume
SciSparc Ltd. (SPRC) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Masks Deep Operational Instability
Investment Thesis • Updated 2025Q4
VerdictNegative: The company's fundamental outlook is constrained by a massive $87.2 million accumulated deficit and a recurring inability to generate positive free cash flow
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding shortfall
"SciSparc faces a challenging outlook characterized by a consistent downward revenue trajectory, evidenced by a 15.2% year-over-year decline in 2025Q4. The company's reliance on external financing to sustain its clinical pipeline, coupled with an accumulated deficit of $87.2 million, suggests significant long-term viability risks. Investors should monitor the company's inability to achieve sustainable commercial scale, as current R&D expenditures continue to outpace revenue generation, further eroding the firm's limited capital base."
Verdict Logic
which necessitates ongoing, dilutive external financing.
SPRC Growth Metrics
SciSparc Ltd. (SPRC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years9.25%
3 Years-14.03%
TTM-48.84%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-139.34%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM89.58%
Return on Capital
10 Years-595.27%
5 Years-98.86%
3 Years-90.98%
Last Year-122.22%
Peers Comparison
Key metrics vs top competitors for SciSparc Ltd. (SPRC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.70 | $231.44K | -0.01 | -34.46% | -1422.78% | -172.92% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $14.82 | $1.42B | -4.81 | — | — | -151.02% | — | |
| $5.29 | $1.95B | -1.82 | 1227.6% | -19019.44% | -366.21% | — | |
| $6.09 | $303.86M | -13.66 | — | — | -81% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — |
Compare SPRC vs Peers
SciSparc Ltd. (SPRC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SPRC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SPRC Frequently Asked Questions
SciSparc Ltd. (SPRC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is SciSparc Ltd.'s revenue?
SciSparc Ltd. (SPRC) reported $2.2M in revenue for fiscal year 2025.
How fast is SciSparc Ltd. growing?
SciSparc Ltd. (SPRC) saw revenue decline by 34.5% over the past year.
Is SPRC profitable?
SciSparc Ltd. (SPRC) reported a net loss of $18.5M for fiscal year 2025.
Dividend & Returns
What is SPRC's return on equity?
SciSparc Ltd. (SPRC) has a return on equity (ROE) of -172.9%. Negative ROE indicates the company is unprofitable.
What is SciSparc Ltd.'s free cash flow?
SciSparc Ltd. (SPRC) had negative free cash flow of $9.2M in fiscal year 2025, likely due to heavy capital investments.